Article
Psychiatry
Erin L. Martin, Justin C. Strickland, Nicolas J. Schlienz, Joel Munson, Heather Jackson, Marcel O. Bonn-Miller, Ryan Vandrey
Summary: This study found that medicinal cannabis use was associated with lower depression symptoms, but not anxiety. Medicinal cannabis users reported better sleep, quality of life, and less pain on average. Initiating medicinal cannabis during the follow-up period was linked to significantly decreased anxiety and depressive symptoms.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Veterinary Sciences
Tom Jukier, Crisanta Cruz-Espindola, Doug Martin, Dawn M. Boothe
Summary: The historical use of marijuana for medicinal purposes includes its use in the treatment of epilepsy. Recently, a highly purified cannabidiol medication has been approved by the FDA for add-on therapy in certain forms of epilepsy. This study focused on determining the disposition of a single dose of cannabidiol in healthy cats, both in fed and fasted states. The pharmacokinetic analysis showed that cannabidiol has a significantly higher bioavailability when administered in a fed state compared to a fasted state, indicating its potential therapeutic value for epilepsy in cats.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Article
Neurosciences
Jag H. Khalsa, Sanjay B. Maggirwar, Greg Bunt
Summary: The COVID-19 epidemic has caused devastating effects on both health and economy, leading to various consequences. While cannabis or CBD are being promoted for treating mental health and neurological complications associated with COVID-19, current research does not provide enough evidence to support their use for such purposes. More research is needed to explore the potential of cannabis or CBD in treating mental health problems related to coronavirus infection and substance use disorders, and caution is advised when prescribing them for clinical indications.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
(2021)
Article
Biology
Gabriela Pesantez Rios, Luciana Armijos Acurio, Ruth Jimbo Sotomayor, Victor Cueva, Ximena Pesantez Rios, Hugo Navarrete Zambrano, Samuel Pascual, Galo Pesantez Cuesta
Summary: This retrospective observational study demonstrates that long-term use of CBD as an adjuvant therapy significantly reduces the frequency, duration, and type of seizures in patients with drug-resistant epilepsy. This is especially effective in improving the most incapacitating seizures, improving the quality of life for patients and their families.
Article
Substance Abuse
Will Lawn, Katie Trinci, Claire Mokrysz, Anna Borissova, Shelan Ofori, Kat Petrilli, Michael Bloomfield, Zarah R. R. Haniff, Daniel Hall, Natalia Fernandez-Vinson, Simiao Wang, Amir Englund, Edward Chesney, Matthew B. B. Wall, Tom P. P. Freeman, H. Valerie Curran
Summary: This study compared the acute effects of cannabis in adolescents and adults, and found no significant differences in subjective effects, verbal memory, and psychotomimetic effects between the two groups. Additionally, it was found that CBD does not mitigate the acute harms caused by THC in both adolescents and adults.
Article
Psychology, Clinical
Claire Mokrysz, Natacha D. C. Shaban, Tom P. Freeman, Will Lawn, Rebecca A. Pope, Chandni Hindocha, Abigail Freeman, Matthew B. Wall, Michael A. P. Bloomfield, Celia J. A. Morgan, David J. Nutt, H. Valerie Curran
Summary: Inhalation of cannabis reliably increases psychotic-like symptoms in healthy cannabis users and may increase the incidence of speech illusion. CBD did not influence the psychotic-like effects of cannabis. Adolescents may be less vulnerable to the acute psychotic-like effects of cannabis compared to adults.
PSYCHOLOGICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Albert Garcia-Romeu, Joshua Elmore, Rhiannon E. Mayhugh, Nicolas J. Schlienz, Erin L. Martin, Justin C. Strickland, Marcel Bonn-Miller, Heather Jackson, Ryan Vandrey
Summary: Medicinal cannabis users perceive benefits from cannabis use for various conditions where traditional treatments are ineffective or unacceptable. However, concerns about cannabis side effects, legality, lack of information, and cost exist. More research and education on the safety and efficacy of medicinal cannabis/cannabinoid use are warranted.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Physical
Malgorzata Zimniewska, Mariola Pawlaczyk, Barbara Romanowska, Agnieszka Gryszczynska, Edyta Kwiatkowska, Patrycja Przybylska
Summary: The study aimed to develop biologically active functional clothing made of pure industrial hemp raw materials, where cannabidiol (CBD) extract applied on the fabric surface strengthened the fiber bioactivity. Human trials showed that wearing the developed functional hemp clothing with CBD extracts applied on the fabric surface was safe and caused improvement of skin condition.
Review
Agriculture, Dairy & Animal Science
Nancy De Briyne, Danny Holmes, Ian Sandler, Enid Stiles, Dharati Szymanski, Sarah Moody, Stephan Neumann, Arturo Anadon
Summary: The increasing availability of cannabis-derived products has led to more cases of toxicosis in pets seen by veterinarians, with a growing interest among animal owners for using these products for their pets. This review examines the situation in Europe and North America, different types of cannabis and its derivatives used historically in animals, the regulatory framework for human and animal use as medicines or supplements, clinical indications, toxicosis, and recommendations and warnings surrounding medical cannabis use.
Article
Environmental Sciences
Danielle Hen-Shoval, Aron Weller, Abraham Weizman, Gal Shoval
Summary: Depression and anxiety disorders are common and growing mental health concerns in adolescents, with antidepressant medication use increasing accordingly. Cannabis use may affect the efficacy of antidepressants, particularly among adolescents, highlighting the need for further research in this area.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Review
Psychiatry
Anna E. Kirkland, Matthew C. Fadus, Staci A. Gruber, Kevin M. Gray, Timothy E. Wilens, Lindsay M. Squeglia
Summary: CBD has become a rapidly growing avenue for research in psychiatry. The most promising preliminary findings are related to the use of CBD in psychotic symptoms and anxiety, but there is currently not enough high-quality evidence to suggest the clinical use of CBD for any psychiatric disorder.
PSYCHIATRY RESEARCH
(2022)
Article
Plant Sciences
Christopher J. Grassa, George D. Weiblen, Jonathan P. Wenger, Clemon Dabney, Shane G. Poplawski, S. Timothy Motley, Todd P. Michael, C. J. Schwartz
Summary: The study found that CBD-type cannabis primarily expresses cannabidiolic acid synthase (CBDAS), while cannabis strains with a balanced THC:CBD ratio express both CBDAS and THCAS. Cannabinoid synthase genes are arranged in tandem structure and embedded within long terminal repeat retrotransposons on chromosome 7.
Article
Psychiatry
Gregoire Cleirec, Esther Desmier, Cristina Lacatus, Simon Lesgourgues, Anais Braun, Claire Peloso, Chanaelle Obadia
Summary: This study provides evidence supporting the use of CBD in treating cannabis use disorder. Inhalation is an effective route of CBD administration, allowing users to self-titrate CBD based on withdrawal symptoms and cravings.
FRONTIERS IN PSYCHIATRY
(2022)
Review
Pharmacology & Pharmacy
Seegehalli M. Anil, Hadar Peeri, Hinanit Koltai
Summary: Inflammation can lead to compromised organ function and cannabis has been used for its anti-inflammatory effects for centuries. The endocannabinoid system is involved in regulating immune system activity and dysfunction of this system can contribute to chronic inflammation. Cannabis produces various phytocannabinoids and other biomolecules that exhibit anti-inflammatory properties. Future research may explore the potential of combining cannabis components with pharmaceutical drugs for inflammation treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Clinical Neurology
Jimmy Li, Cassandra C. Areal, Denahin Hinnoutondji Toffa, Daphne Citherlet, Charles Deacon, Didier Jutras-Aswad, Mark Robert Keezer, Dang Khoa Nguyen
Summary: This scoping review summarized the literature on non-medical cannabis use in people with epilepsy (PWE), focusing on their experience, habits, and beliefs regarding non-medical cannabis. The majority of studies suggested that non-medical cannabis could aid in seizure control for PWE, but the research in this area is sparse and heterogeneous, and further research is needed to better understand PWE's experience, habits, and beliefs regarding non-medical cannabis.
FRONTIERS IN NEUROLOGY
(2023)